Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This refers to an investigational autologous cell therapy being studied at Sheba Medical Center in Israel for the treatment of autism spectrum disorder (ASD). The therapy involves a single intravenous infusion of the patient's own umbilical cord blood that was banked at birth. As a biologic therapy, it consists of autologous cells hypothesized to work by modulating inflammatory processes in the brain through paracrine signaling. The treatment aims to reduce neuroinflammation and regulate aberrant neural connectivity pathways associated with autism. Sheba Medical Center has conducted Phase II clinical trials evaluating the efficacy of this approach in children aged 1.5 to 12 years.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autologous umbilical cord blood (Sheba Medical Center, f110c2).